Cargando…
Repositioning of histamine H(1) receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2
The spread of the corona virus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been intensifying in the past year, posing a huge threat to global health. There is an urgent need for effective drugs and vaccines to fight the COVID-19, but th...
Autores principales: | Ge, Shuai, Wang, Xiangjun, Hou, Yajing, Lv, Yuexin, Wang, Cheng, He, Huaizhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826143/ https://www.ncbi.nlm.nih.gov/pubmed/33497607 http://dx.doi.org/10.1016/j.ejphar.2021.173897 |
Ejemplares similares
-
Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2
por: Ge, Shuai, et al.
Publicado: (2021) -
Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis
por: Hou, Yajing, et al.
Publicado: (2021) -
Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus
por: Wang, Nan, et al.
Publicado: (2020) -
Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2
por: Zhang, Yongjing, et al.
Publicado: (2021) -
Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro
por: Lu, Jiayu, et al.
Publicado: (2021)